(Jan 13): AbbVie Inc signed an agreement with the US government to lower some drug prices and invest US$100 billion (RM405.6 billion) domestically in exchange for an exemption from certain tariffs. AbbVie will invest the US$100 billion in US research, development and capital investments, including manufacturing, over the next decade. The company did not immediately respond to a request for comment about how the funds would be specifically used. AbbVie will also lower prices in the Medicaid programme and offer some drugs directly to patients through a Trump-branded website, TrumpRx, according to the release. In exchange, AbbVie will be exempt from tariffs and “future price mandates”, the company said.

Source: The Edge Markets January 13, 2026 08:08 UTC